AI Duo Targets Human Error to Fix Ailing CNS Clinical Trials

BOSTON and PRAGUE – May 14, 2026 – In a move poised to reshape the landscape of neurological and psychiatric drug development, clinical trial data specialist EMA Wellness (EMAW) has entered into an exclusive partnership with the AI firm Mira Analytics. The collaboration will deploy sophisticated artificial intelligence to tackle one of the most persistent and costly problems in medicine: the subjectivity and variability that plague clinical trials for Central Nervous System (CNS) disorders.

By integrating Mira's AI models directly into EMAW's global data capture platform, the companies aim to create a new standard for data quality, moving from slow, retrospective analysis to real-time, continuous quality assurance. This alliance promises not only to improve the reliability of trial results but also to potentially slash the time and billions of dollars required to bring new treatments for conditions like depression, anxiety, and Alzheimer's to patients.

Tackling the Achilles' Heel of CNS Research

Developing drugs for CNS disorders is notoriously difficult. The path from lab to pharmacy is long, expensive, and fraught with failure. Industry data reveals a sobering reality: less than 27% of CNS studies successfully transition from Phase 2 to regulatory approval, a far lower rate than in many other therapeutic areas. A primary culprit for this high attrition rate is the reliance on subjective clinical endpoints.

Unlike a blood pressure reading or a tumor measurement, the severity of conditions like major depressive disorder or schizophrenia is assessed through structured clinical interviews and rating scales, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) or the Hamilton Anxiety Rating Scale (HAM-A). The scores are determined by a human rater's interpretation of a patient's responses. This introduces a significant risk of variability. Raters in different countries, or even in the same facility, may have subtle differences in technique, training, or interpretation, leading to inconsistent data that can obscure a drug's true effect.

This “noise” in the data can be catastrophic for a trial, potentially causing a genuinely effective drug to appear useless or forcing sponsors to enroll thousands of additional patients to achieve statistical significance, driving up costs and delaying progress. The partnership between EMA Wellness and Mira Analytics is designed to confront this fundamental challenge head-on.

A 'Digital Umpire' for Clinical Data

The collaboration creates a powerful, integrated system. EMAW's established GIANT™ platform, already used in over 25 countries, serves as the robust data collection engine. It standardizes the capture of multimodal data, including the crucial audio and video recordings of clinical interviews, within a single, compliant architecture. This provides the high-quality, standardized input necessary for Mira's AI to perform its analysis.

Mira's AI models then act as a tireless, objective digital umpire. Trained on thousands of clinical interviews from previous Phase 2 and 3 trials, the models analyze the full context of each session—including text, audio, and video—to generate an independent, reproducible score. The system's true power lies in its real-time surveillance capability. If the AI-generated score significantly differs from the human rater's score, it automatically flags the interview for review. This allows trial sponsors to identify potential issues with rater performance or site-level inconsistencies as they happen, not months later when the data is locked.

“Our focus is on ingesting high-quality, multi modal clinical data and making it actionable in real time,” said Colin Bower, co-founder and CEO of EMA Wellness. “By integrating Mira's models directly into our platform, sponsors can move from retrospective review to continuous quality assurance across their trials.”

This approach addresses what Mira co-founder and CEO, Adam Kolar, calls a critical gap. “Clinical interviews remain the most information-rich data we collect in CNS trials, and also the hardest to measure consistently,” he stated. “That’s the gap our models are built to close.”

According to Mira, its models have demonstrated accuracy comparable to expert human raters, reporting 95.2% accuracy on central rater training exercises and a minimal point difference in a Phase 2b study. The models are already being deployed in ongoing Phase 3 trials, showcasing their readiness for late-stage clinical validation.

Navigating a New Regulatory Frontier

The timing of this partnership is critical, as global regulatory bodies are actively shaping the future of AI in drug development. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have recently moved to establish clear guidelines for the responsible use of AI/ML.

In January 2026, the agencies jointly released “Guiding Principles of Good AI Practice in Drug Development,” emphasizing a human-centric, risk-based approach. This followed the EMA's finalized 2024 reflection paper, which requires full transparency for any AI tool that could impact regulatory outcomes, including those used for endpoint analysis. Regulators demand that models be validated, explainable, and “frozen” before a trial is unblinded to ensure data integrity.

The EMAW-Mira solution appears designed to meet these emerging standards. The companies emphasize the explainability of Mira's AI, which allows clinicians to trace a score back to specific moments in an interview, building trust and facilitating effective review. By providing a full audit trail within a validated, compliant platform, the partnership provides the transparency and documentation that regulators are beginning to demand, positioning them at the forefront of this technological shift.

The Race for Efficiency and Market Leadership

Beyond the scientific and regulatory implications, this exclusive partnership represents a strategic maneuver in the rapidly expanding market for AI in clinical trials, a sector projected to grow from $2.7 billion in 2025 to over $8.5 billion by 2030. While large technology providers like Medidata and IQVIA offer broad, multi-faceted platforms, the EMAW-Mira alliance is distinguished by its highly specialized focus on solving a singular, high-value problem in the difficult CNS space.

The potential return on investment is enormous. Experts suggest that AI could reduce the typical 10-12 year drug development timeline by half. By ensuring cleaner data and enabling faster, more confident go/no-go decisions, the technology could save pharmaceutical companies hundreds of millions, if not billions, of dollars per drug program. As Bower noted, the integrated solution is also “turn key,” eliminating the complex and costly need for sponsors to manage separate vendors, data transfers, and validation processes.

By automating quality control, the platform allows expert human clinicians to focus their efforts on the most complex cases flagged by the AI, rather than manually reviewing hundreds or thousands of interviews. This targeted approach not only improves quality but also significantly reduces the manual effort and cost associated with large-scale central review, ultimately accelerating the entire clinical trial process and enabling a new era of precision medicine.